Vera Therapeutics (NASDAQ:VERA) reported final efficacy results from its Phase III ORIGIN trial evaluating atacicept, ...
The oral, once-daily EGFR inhibitor is now in specialty distribution for patients whose disease progressed after ...
AstraZeneca announced the US availability of ZEGFROVY® (sunvozertinib) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal ...
ZEGFROVY is now available in the US for post-platinum EGFR exon 20 insertion NSCLC after a 46% response rate in WU-KONG1B.
Launch expands AstraZeneca’s commitment to addressing substantial unmet need across the spectrum of EGFR-mutated lung cancer ...
In a cross-sectional study of 240 patients with chronic kidney disease, higher serum BDNF levels and a ...
Approval based on Phase 3 data showing unprecedented functional cure rates compared to standard of care – – Six-month ...
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B (CHB) virus infection in combination ...
Your kidneys can quietly lose most of their work before you ever feel anything is wrong, and the signs that do slip through ...
Two oral presentations to highlight new 76-week data showing sustained proteinuria reduction and continued eGFR stabilization with a consistent ...
Chronic Kidney Disease (CKD) is a progressive condition in which the kidneys gradually lose their ability to filter waste ...
Depending on dose, firmonertinib shrank tumors in 43% to 68% of patients as a first treatment for EGFR PACC-mutant lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results